ADC Therapeutics, a Swiss cancer drug developer, has postponed its U.S. IPO, citing adverse conditions, reported Reuters. The firm was planning on raising $200 million for the IPO. ADC’s backers include Auven Therapeutics and AstraZeneca.
ADC Therapeutics puts IPO on hold: Reuters
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.